Modulation of angiogenesis
AssigneeUniversity of Kentucky Research Foundation
InventorsBalamurali Krishna Ambati, Jayakrishna Ambati, Nirbhai Singh
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds, compositions, and methods for the treatment of traits, diseases and conditions that respond to the modulation of angiogenic growth factor bioavailability or biological activity.
Claims42
A method of treating or preventing a condition associated with decreased vascularity in a subject, the method comprising administering to the subject a compound that regulates the bioavailability or biological activity of VEGF or PlGF by modulating the availability of a VEGF or PlGF inactivating agent, wherein the administering is sufficient to treat or prevent the condition in the subject.
A short interfering nucleic acid (siNA) molecule that promotes VEGF bioavailability by down-regulating the expression of a polypeptide encoded by the fms-like tyrosine kinase (Flt-1) gene.
A composition comprising an siRNA molecule having a length of 19 to 50 nucleotides and having a nucleotide sequence of any one of SEQ ID NO:1, 2, 3, 4, 5, 6, or 7, or a complement thereof, and a pharmaceutically acceptable carrier.
A method of identifying a compound that regulates the bioavailability or biological activity of VEGF or PlGF in vivo or in situ, the method comprising:
- a) contacting corneal tissue with a test compound that regulates, or is believed to regulate:
- i) the expression of a VEGF or PlGF inactivating agent;
- or
- ii) the ability of the VEGF or PlGF inactivating agent to bind to VEGF or PlGF;
- b) measuring the bioavailability or biological activity of VEGF or PlGF;
- and
- c) identifying a compound that regulates the bioavailability or biological activity of VEGF or PlGF.
Dependencies are inferred from the claim text.